Positron Emission Tomography (PET) plays a central role in modern nuclear medicine, enabling the visualization of biological processes in vivo for applications ranging from oncology to neurology, cardiovascular imaging, and drug development. By providing a non-invasive view of metabolic activity throughout the body, PET supports diagnosis, treatment assessment, and the evaluation of therapeutic response. Despite its clinical relevance, PET technology has changed only incrementally over the past decades, while cost and performance limitations continue to restrict broader access. Nuclyscan is Terapet’s next-generation total-body PET system, developed to overcome the conventional trade-off between resolution, sensitivity, and cost. Built on a proprietary gamma-ray detection technology, it is designed to deliver high-performance imaging in a compact and scalable system, supporting more accessible and data-rich precision imaging.